CagriSema:
Complete Protocol Guide

CagriSema

Semaglutide

Tirzepatide

Weeks 1–4

Starting dose for both components. GI side effects are most common during this adaptation phase — slow escalation is essential.

Weeks 5–8

First dose increase. Most users notice appetite suppression strengthening meaningfully here. Weight loss typically begins visibly.

Weeks 9–16

Full therapeutic activity from both pathways begins here. Gastric emptying significantly slowed. Caloric intake reduction most pronounced.

Weeks 17+

Maintenance range. The Phase 2 SCALE data generating 15.6% weight loss used 2.4mg of each component. Titrate to tolerance.

Eat smaller, more frequent meals. Avoid high-fat meals that further slow gastric emptying. Dose after the evening meal rather than in the morning. If nausea is severe, hold dose escalation at the current level for an additional 2 weeks before increasing.

The primary mechanism — reduced appetite is the intended outcome. Ensure adequate protein intake (1.6–2.2g/kg bodyweight) to preserve lean mass during fat loss. Do not reduce protein even when overall appetite is significantly suppressed.

Typically resolves within 1–2 weeks of each dose increase. Ensure adequate caloric intake — severe restriction combined with dual-pathway appetite suppression can produce excessive energy deficit. Target a 500–750 calorie deficit, not extreme restriction.

Minor redness, swelling, or itching at injection sites is normal. Rotate injection sites weekly. Allow needle insertion at a 45° angle for subcutaneous tissue. If persistent lump develops, allow site to fully recover before re-using.

Can I switch from semaglutide to CagriSema mid-protocol?

Yes — and this is one of CagriSema's most common use cases. If you've been running semaglutide for several months and weight loss has plateaued, switching to or adding cagrilintide targets a receptor that has not been desensitized by your existing protocol. Start the combination at a dose matching your current semaglutide dose and follow the escalation schedule from that point.

Do I need to do a loading protocol like with tirzepatide?

No loading phase — CagriSema uses the same slow weekly escalation approach as semaglutide monotherapy. The key difference is that the dual-pathway activation makes GI side effects more pronounced than with semaglutide alone, so holding each dose level for 4 full weeks before increasing (rather than the 2–4 week semaglutide escalation) reduces adaptation discomfort.

What does the cagrilintide component actually add?

Cagrilintide adds amylin receptor activation — a satiety pathway that semaglutide alone never touches. Amylin acts in the area postrema and nucleus tractus solitarius, not the hypothalamic regions targeted by GLP-1. The result is suppression from two independent neural circuits simultaneously. Most users report that the combination produces a qualitatively different kind of fullness — not just reduced hunger, but a persistent inter-meal satiety that makes adherence substantially easier.

Is CagriSema safe for long-term use?

Both component compounds have established safety profiles: semaglutide from years of pharmaceutical use, cagrilintide from the SCALE Phase 2 program. No new safety signals emerged from the combination that were not already known for semaglutide monotherapy. As with all GLP-1-based protocols, appropriate medical oversight and protein intake maintenance are recommended for extended use.